GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®
GoodRx the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly’s Employer Connect independent program administrators, GoodRx enables self-insured employers to access Zepbound KwikPen at a set price of $449 across all doses, with the flexibility to further subsidize the cost for employees at the pharmacy counter.
Employers are navigating rising demand for GLP-1 obesity treatments and need predictable, transparent affordability solutions,” said Laura Jensen, Chief Commercial Officer & President of Pharma Direct at GoodRx. “Our collaboration with Lilly demonstrates how GoodRx connects manufacturer pricing and employer contributions in a single infrastructure. The result is a scalable model that expands access to Zepbound while supporting long-term sustainability for employers.
A Simplified Model for Employer-Sponsored Access
GoodRx Employer Direct enables employers to support access to Zepbound KwikPen without altering their core health benefit structure. Employer contributions to Lilly’s Employer Connect $449 price are applied seamlessly to the medication price, creating a predictable and more transparent pathway for high-demand obesity management medicines. The program is designed to complement, not replace, traditional health plans, offering a simplified access pathway outside traditional formulary controls. Plan sponsors retain flexibility and control over contribution amounts.
Employers may also deploy a branded version of GoodRx for Weight Loss, which is a direct-to-consumer telemedicine solution that simplifies every step of the GLP-1 treatment journey. This end-to-end model enables employees to meet with licensed healthcare providers, discuss treatment options, complete eligibility assessments, and — when clinically appropriate and consistent with FDA labeling guidelines — receive a prescription for Zepbound KwikPen.
Employers continue to tell us they want to better support their employees’ health but face real challenges in providing coverage for obesity management medicines,” said Kevin Hern, Senior Vice President, Lilly Employer, Lilly USA. “We’re excited to collaborate with organizations that share our commitment to removing friction and providing flexible, transparent solutions for employers to expand access to obesity management medicines for people who need them.”
GoodRx Powers An Integrated Access Infrastructure
The collaboration highlights the strength of the GoodRx platform in integrating clinical access, manufacturer pricing and employer funding within a single infrastructure. Through GoodRx Pharma Direct, manufacturers operationalize discounted cash pricing directly within the GoodRx experience. Employer Direct then extends that infrastructure to employers, enabling real-time application of employer contributions on top of manufacturer pricing at the pharmacy counter. Ultimately, GoodRx creates a unified pathway linking manufacturers, employers, pharmacies, and patients — reducing friction and expanding access to important therapies like Zepbound KwikPen.
About GoodRx
GoodRx is the leading platform for prescription savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.
Source link: https://www.businesswire.com/
